Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2008-09-24
2010-12-14
Blanchard, David J. (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S141100, C424S143100, C424S156100, C435S069600, C530S387300, C530S387500, C530S387700, C530S388100, C530S388850
Reexamination Certificate
active
07850966
ABSTRACT:
The present invention concerns novel antibody variants, particularly anti-HER2 antibody variants having substitutions at positions within the variable domains of the heavy and light chains.
REFERENCES:
patent: 4968603 (1990-11-01), Slamon et al.
patent: 5677171 (1997-10-01), Hudziak et al.
patent: 5783186 (1998-07-01), Arakawa et al.
patent: 5821337 (1998-10-01), Carter et al.
patent: 5824311 (1998-10-01), Greene et al.
patent: 5837234 (1998-11-01), Gentile et al.
patent: 2002/0035736 (2002-03-01), Erickson et al.
patent: WO 92/20798 (1992-11-01), None
patent: WO 92/22653 (1992-12-01), None
patent: WO 93/21319 (1993-10-01), None
patent: WO 94/00136 (1994-01-01), None
patent: WO 94/22478 (1994-10-01), None
patent: WO 96/16673 (1996-06-01), None
patent: WO 03/068801 (2003-08-01), None
(Paul, Fundamental Immunology, 3rd Edition, 1993, pp. 292-295, under the heading “Fv Structure and Diversity in Three Dimensions”).
Rudikoff et al (Proc. Natl. Acad. Sci. USA, 79:1979-1983, Mar. 1982).
Casset et al. ((2003) BBRC 307, 198-205).
Burgess et al, Journal of Cell Biology vol. 111 Nov. 1990 2129-2138.
Lazar et al Molecular and Cellular Biology Mar. 1988 vol. 8 No. 3 1247-1252.
Colman et al (Research in Immunology 1994, 145:33-36).
Ibragimova and Eade (Biophysical Journal, Oct. 1999, vol. 77, pp. 2191-2198).
Gerstner, R. B. et al., “Sequence Plasticity in the Antigen-Binding Site of a Therapeutic Anti-HER 2 Antibody”, Journal of Molecular Biology, London, GB, vol. 321 (Aug. 30, 2002), pp. 851-862 XP002972421 ISSN: 0022-2836.
Lowman, H. B. et al., “Phage Display of Peptide Libraries on Protein Scaffolds” Methods in Molecular Biology, Human Press Inc., Clifton, NJ, US, vol. 87 (1998) pp. 249-264 XP000985641.
Sidhu, S. S. et al., “Phage Display for Selection of Novel Binding Peptides”, Methods in Enzymology, Academic Press Inc., san Deigo, CA, US, vol. 328, (2000) pp. 333-363 XP000984091 ISSN: 0076-6879.
Aasland et al., “Expression of oncogenes in thyroid tumours: coexpression of c-erbB2
euand c-erbB”,Br. J. Cancer, 57:358-363 (1988).
Arteaga et al., “p185c-erbB-2signaling enhances cisplatin-induced cytotoxicity in human breat carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair”,Cancer Res., 54:3758-3765 (1994).
Bacus et al., “Differentiation of cultured human breast cancer cells (AU-565 and MCF-7) associated with loss of cell surface HER-2
euantigen”,Molecular Carcinogenesis, 3:350-362 (1990).
Bacus et al., “Tumor-inhibitory monoclonal antibodies to the HER-2
eu receptor induce differentiation of human breast cancer cells”,Cancer Research, 52:2580-2589 (1992).
Borst et al., “Oncongene alterations in endometrial carcinoma”,Gynecol. Oncol., 38:364-366 (1990).
Carter et al., “Humanization of an anti-p185HER2antibody for human cancer therapy”,Proc. Nat. Acad. Sci. USA89: 4285-4289 (1992).
Chothia et al., “Conformations of immunoglobulin hypervariable regions”,Nature, 342(6252):877-83 (1989).
Cobleigh et al., “Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastic disease”,J Clin. Oncol., 17: 2639-2648 (1999).
Cohen et al., “Expression pattern of theneu(NGL) gene-encoded growth factor receptor protein (p185neu) in normal and transformed epithelial tissues of the digestive tract,”Oncogene, 4:81-88 (1989).
D'souza et al., “Overexpression of ERBB2 in human mammary epithelial cells signals inhibition of transcription of the E-cadherin gene”,Proc. Natl. Acad. Sci., 91:7202-7206 (1994).
Drebin et al., “Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies”,Cell, 41:695-706 (1985).
Drebin et al., “Monoclonal antibodies reactive with distinct domains of theneuoncongene-encoded p185 molecule exert synergistic anti-tumor effects in vivo”,Oncogene, 2:273-277 (1988).
Eigenbrot et al., “X-ray structures of the antigen-binding domains from three variants of humanized anti-p185HER2antibody 4D5 and comparison with molecular modeling”,J Mol Bio, 229(4):969-95 (1993).
Fendly et al., “Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2
eugene product”,Cancer Res., 50(5):1550-8 (1990).
Fukushigi et al., “Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line”,Mol Cell Biol., 6:955-958 (1986).
Gallivan, J. P. & Dougherty, D. A., “Cation-π interactions in structural biology”,Proc Natl. Acad. Sci. USA, 96(17):9459-64 (1999).
Gu et al., “Overexpression of her-2
euin human prostate cancer and benign hyperplasia”,Cancer Lett., 99:185-9 (1996).
Geurin et al., “Overexpression of either c-mycor c-erbB-2
eupro-oncogenes in human breast carcinomas: correlations with poor prognosis”,Oncogene Res., 3:21-31 (1988).
Hancock et al., “A monoclonal antibody against the c-erbB-2 protein enhances the cytoxicity ofcis-diamminedichloroplatinum against human breast and ovarian tumor cell”,Cancer Res., 51:4575-4580 (1991).
Harwerth et al., “Monoclonal antibodies against the extracellular domain of the erbB-2 receptor function as partial ligand agonists”,J Biol. Chem., 267:15160-15167 (1992).
Holmes et al., “Identification of hergulin, a specific activator of p185erbB2”,Science, 256:1205-1210 (1992).
Hudziak et al., “p185HER2monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor”,Mol Cell Biol. 9(3):1165-72 (1989).
Jones et al., “Replacing the complementarity-determining regions in a human antibody with those from a mouse”,Nature, 321:522-525 (1986).
Kasprzyk et al., “Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies”,Cancer Research, 52:2771-2776 (1992).
Kelley et al., “Antigen binding thermodynamics and antiproliferative effects of chimeric and humanized anti-p185HER2antibody fab fragments”,Biochemistry, 31(24):5434-411, (1992).
Kelley, R.F. & O'Connell, M.P., “Thermodynamic analysis of an antibody functional epitope”,Biochemistry, 32(27):6828-35 (1993).
Kern et al., “p185neuexpression in human lung adenocarcinomas predicts shortened survival”,Cancer Res., 50:5184-5191 (1990).
King et al., Amplification of a novel v-erbB-related gene in a human mammary carcinoma:,Science, 229:974-976 (1985).
Klapper et al. , “A subclass of tumor-inhibitory monoclonal antibodies to erbB-2/HER2 blocks crosstalk with growth factor receptors”,Oncogene, 14:2099-2109 (1997).
Kotts et al., “Differential growth inhibition of human carcinoma cells exposed to monoclonal antibodies directed against the extracellular domain of the HER2/ERBB2 protooncongene”, In Vitro, 26(3):59A (1990).
Kumar et al., “Regulation of phosphorylation of the c-erbB-2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells”,Mol. Cell. Biol., 11(2):979-986 (1991).
Lewis et al., “Differential responses of human tumor cell lines to anti-p185HER2monoclonal antibodies”,Cancer Immunol. Immunother., 37:255-263 (1993).
Lewis et al., “Growth regulation of human breast and ovarian tumor cells by heregulin: evidence for the requirement of erbB2 as a critical component in mediating heregulin responsiveness”,Cancer Research, 56:1457-1465 (1996).
Lowman, H. B., “Phage display of peptide libraries on protein scaffolds”,Methods Mol Biol, 87:249-64 (1998).
Maier et al., “Requirements for the internaliz
Carter Paul J.
Gerstner Resi B.
Lowman Henry B.
Arnold & Porter LLP
Blanchard David J.
Dreger Ginger R.
Genentech Inc.
Marschang Diane
LandOfFree
Method of treating breast cancer using anti-HER2 antibody... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating breast cancer using anti-HER2 antibody..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating breast cancer using anti-HER2 antibody... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4183130